INmune Bio Inc. (INMB)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Pharmaceuticals	50.00K	14.00K	155.00K	374.00K	181.00K
Pharmaceuticals Growth	257.14%	-90.97%	-58.56%	106.63%	1545.45%
Total	50.00K	14.00K	155.00K	374.00K	181.00K
Total Growth	257.14%	-90.97%	-58.56%	106.63%	1545.45%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
United States	50.00K	14.00K	155.00K	374.00K	181.00K
United States Growth	257.14%	-90.97%	-58.56%	106.63%	1545.45%
Total	50.00K	14.00K	155.00K	374.00K	181.00K
Total Growth	257.14%	-90.97%	-58.56%	106.63%	1545.45%

Data Source: S&P Global Market Intelligence Last updated: Mar 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 18, 2026

Data Sources Report a data error